MDT

84.21

-0.14%↓

VEEV

226.67

-0.19%↓

106.17

-0.03%↓

WBA

-0.09%↓

CHE

555.99

+0.34%↑

MDT

84.21

-0.14%↓

VEEV

226.67

-0.19%↓

106.17

-0.03%↓

WBA

-0.09%↓

CHE

555.99

+0.34%↑

MDT

84.21

-0.14%↓

VEEV

226.67

-0.19%↓

106.17

-0.03%↓

WBA

-0.09%↓

CHE

555.99

+0.34%↑

MDT

84.21

-0.14%↓

VEEV

226.67

-0.19%↓

106.17

-0.03%↓

WBA

-0.09%↓

CHE

555.99

+0.34%↑

MDT

84.21

-0.14%↓

VEEV

226.67

-0.19%↓

106.17

-0.03%↓

WBA

-0.09%↓

CHE

555.99

+0.34%↑

Начало・Списък с акции・ESPERION THERAPEUTICS INC

ESPERION THERAPEUTICS INC

Отворен

СекторЗдравеопазване

0.93 9.41

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

0.85

Максимум

0.92

Ключови измерители
By Trading Economics
Приходи	8.2M -21M
Продажби	17M 69M
EPS	-0.101
Марж на печалбата	-30.845
Служители	304
EBITDA	9.5M -4.9M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+638.64% upside

Дивиденти
By Dow Jones
Следващи печалби	6.05.2025 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-166M 169M
Предишно отваряне	-8.48
Предишно затваряне	0.93

Техническа оценка

By Trading Central

Увереност

Weak Bearish Evidence

0.8191 / 0.95 Подкрепа & съпротива

ESPERION THERAPEUTICS INC Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

24.04.2025 г., 23:54 ч. UTC

Горещи акции

Stocks to Watch: Alphabet, Intel, AppFolio

24.04.2025 г., 23:51 ч. UTC

Пазарно говорене

Gold Edges Higher, Supported by U.S. Dollar Weakness -- Market Talk

24.04.2025 г., 23:46 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

24.04.2025 г., 23:46 ч. UTC

Пазарно говорене

Nikkei May Rise on Hopes for Easing U.S.-China Trade Tensions -- Market Talk

24.04.2025 г., 23:37 ч. UTC

Топ новини

Big Tech Braces for Tariff-Induced Advertising Slowdown -- WSJ

24.04.2025 г., 23:36 ч. UTC

Топ новини

Tokyo Consumer Inflation Accelerates in April as Companies Raise Prices

24.04.2025 г., 23:13 ч. UTC

Топ новини

Печалби

Google's Earnings Power Holds Up in Global Turbulence -- Update

24.04.2025 г., 23:09 ч. UTC

Топ новини

Trump Initiatives Knocked Back in a New Round of Court Rulings -- 2nd Update

24.04.2025 г., 23:02 ч. UTC

Придобивния, сливания и поглъщания

SK Telecom to Sell 10.8M Kakao Shares via After-Hours Block Trading

24.04.2025 г., 23:02 ч. UTC

Придобивния, сливания и поглъщания

SK Telecom to Dispose of 2.4% Stake in Kakao to Raise KRW413.27B

24.04.2025 г., 22:51 ч. UTC

Топ новини

Придобивния, сливания и поглъщания

Germany's Merck Nears Roughly $3.5 Billion Deal for SpringWorks -- Update

24.04.2025 г., 22:48 ч. UTC

Топ новини

Walmart Walks the DEI Tightrope in Latest Proxy Statement -- Barrons.com

24.04.2025 г., 22:47 ч. UTC

Пазарно говорене

Intel Remains in Tough Position, CFRA Research Analyst Says -- Market Talk

24.04.2025 г., 22:38 ч. UTC

Пазарно говорене

Печалби

Tariffs Hurt Intel's 2Q Outlook as CFO Warns Economic Slowdown is Likely -- Market Talk

24.04.2025 г., 22:24 ч. UTC

Печалби

Aluminum Corp. of China: Increase in Product Sales Supported 1Q Results >2600.HK

24.04.2025 г., 22:24 ч. UTC

Печалби

Aluminum Corp. of China 1Q Rev CNY55.78B Vs. CNY48.96B >2600.HK

24.04.2025 г., 22:24 ч. UTC

Пазарно говорене

Печалби

Intel's Comeback Involves More Engineers, More In-Office Work -- Market Talk

24.04.2025 г., 22:23 ч. UTC

Печалби

Aluminum Corp. of China 1Q Net CNY3.54B Vs. Net CNY2.23B >2600.HK

24.04.2025 г., 22:11 ч. UTC

Пазарно говорене

Печалби

Global Equities Roundup: Market Talk

24.04.2025 г., 22:11 ч. UTC

Пазарно говорене

Печалби

Intel CEO: Layoffs Will Simplify Company Structure -- Market Talk

24.04.2025 г., 22:09 ч. UTC

Топ новини

Печалби

Intel Cuts Outlook, Says Layoffs Are in Store -- Update

24.04.2025 г., 22:00 ч. UTC

Пазарно говорене

Печалби

T-Mobile's Key Subscriber Metric Disappoints Despite Earnings Beat -- Market Talk

24.04.2025 г., 21:39 ч. UTC

Топ новини

Trump Initiatives Knocked Back in a New Round of Court Rulings -- WSJ

24.04.2025 г., 21:24 ч. UTC

Топ новини

Печалби

Bristol Myers Reports Better-Than-Expected Earnings. The Future Is Cloudy. -- Barrons.com

24.04.2025 г., 21:24 ч. UTC

Топ новини

Печалби

Google's Earnings Power Holds Up in Global Turbulence -- WSJ

24.04.2025 г., 21:23 ч. UTC

Топ новини

Печалби

Intel Cuts Outlook, Says Layoffs Are in Store -- WSJ

24.04.2025 г., 21:04 ч. UTC

Печалби

T-Mobile Reports Strong Earnings but Its Wireless Results Disappoint. The Stock Is Sliding. -- Barrons.com

24.04.2025 г., 21:03 ч. UTC

Печалби

Agnico-Eagle Mines Believes Its Rev Structure Will Be Largely Unaffected by the Tariffs >AEM.T

24.04.2025 г., 21:03 ч. UTC

Печалби

Agnico-Eagle Mines Total Expected Capex for 2025 Still Estimated at $1.75 B to $1.95 B >AEM.T

24.04.2025 г., 21:02 ч. UTC

Печалби

Agnico-Eagle Mines Positioned to Achieve 2025 AISC Per Ounce Guidance of $1,250 to $1,300. >AEM.T

Сравнение с други в отрасъла

Ценова промяна

ESPERION THERAPEUTICS INC Прогноза

Ценова цел

By TipRanks

638.64% нагоре

12-месечна прогноза

Среден 6.5 USD 638.64%

Висок 16 USD

Нисък 2 USD

Според 6 анализатори от Wall Street, предложили 12-месечна ценова цел за ESPERION THERAPEUTICS INC през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

6 ratings

Купи

Задържане

Продай

Според 6 анализатори, дали борсови рейтинги на ESPERION THERAPEUTICS INC през последните 3 месеца.

Техническа оценка

By Trading Central

0.8191 / 0.95Подкрепа & съпротива

Bearish events outweigh bullish events.

All events are bearish.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно ESPERION THERAPEUTICS INC

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.